摘要
目的探究临床上重症脓毒血症的治疗中,采用连续性血液净化的效果和价值。方法选取2018年6月至2021年6月南宁市第一人民医院收治的100例重症脓毒血症患者作为研究对象,采用随机数字表法分为对照组(50例)和试验组(50例),对照组采用常规治疗方法,试验组采用连续性血液净化治疗方法。比较两组患者的不良反应总发生率、临床疗效、血小板含量、肾功能指标以及炎症因子水平。结果试验组的不良反应总发生率低于对照组,且临床疗效高于对照组,血小板含量低于对照组,差异有统计学意义(P<0.05);治疗前两组的肌酐、尿素氮、C反应蛋白(CRP)、降钙素原(PCT)、肿瘤坏死因子-α(TNF-α)水平比较,差异无统计学意义(P>0.05),治疗后,试验组的肌酐、尿素氮、CRP、PCT、TNF-α低于对照组,差异有统计学意义(P<0.05)。结论对重症脓毒血症患者进行连续性血液净化治疗的效果显著,能够改善患者的肾功能指标以及炎症因子水平。
Objective To explore the treatment of severe sepsis in clinical practice,and the effectiveness and value of continuous blood purification.Methods A total of 100 patients with severe sepsis from June 2018 to June 2021 admitted to the First People's Hospital of Nanning City were selected for the study.A random number table method was used to divide them into a control group(50 cases)and an experimental group(50 cases).Conventional treatment methods were applied to the control group,while the experimental group received continuous blood purification treatment.The total incidence of adverse reactions,clinical efficacy,platelet content,renal function indicators,and levels of inflammatory factors between two groups were compared.Results The total incidence of adverse reactions in the experimental group was lower than that in the control group,and the clinical efficacy was higher than that in the control group,and the platelet content was lower than that in the control group,and the differences were statistically significant(P<0.05).The levels of creatinine,urea nitrogen,C-reactive protein(CRP),procalcitonin(PCT),and tumor necrosis factor-α(TNF-α)in the two groups before treatment showed no statistically significant differences(P>0.05).After treatment,the creatinine,urea nitrogen,CRP,PCT,and TNF-αlevels in the experimental group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion Continuous blood purification therapy for patients with severe sepsis has a significant effect,which can significantly improve their renal function indicators and inflammatory factor levels.
作者
潘永江
邹鹏鸣
梁安玉
PAN Yongjiang;ZOU Pengming;LIANG Anyu(Department of Laboratory,Nanning First People's Hospital,Guangxi Zhuang Autonomous Region,Nanning530022,China)
出处
《中国当代医药》
CAS
2024年第7期29-32,共4页
China Modern Medicine
基金
广西壮族自治区卫生健康委自筹经费科研课题(Z-A20231148)。
